Form 4: Adaptimmune Therapeutics' Chief Medical Officer Sells Shares to Cover Tax Obligations

Elliot Norry, Chief Medical Officer of Adaptimmune Therapeutics PLC, sold American Depositary Shares (ADS) to cover tax withholding obligations related to the exercise of vested RSU-style share options.

Summary

• Elliot Norry, the Chief Medical Officer of Adaptimmune Therapeutics PLC, filed a Form 4 detailing changes in beneficial ownership.
• The transactions involved the sale of American Depositary Shares (ADS) representing ordinary shares of the Issuer.
• These sales were executed on January 13, 2025, and January 15, 2025, at weighted average prices ranging from $0.5748 to $0.5879.
• The sales were conducted to cover tax withholding obligations and associated sale costs related to the exercise of vested RSU-style share options.
• The ADSs were obtained from the exercise of approximately 25% of RSU-style share options granted on January 11, 2021, January 12, 2022 and January 15, 2024.
• Following these transactions, Norry continues to hold 94,638 ADSs and RSU-style options and other options covering an aggregate of 8,850,794 ordinary shares of the Issuer.

Sentiment

Score: 6

Explanation: The document reflects routine transactions related to executive compensation. It's neutral in sentiment as it doesn't indicate any fundamental changes in the company's prospects.

Positives

• The transactions are part of a pre-existing option plan, suggesting a structured approach to equity compensation.
• The reporting person continues to hold a significant number of ADSs and options, indicating continued alignment with the company's success.

Industry Context

Sales of shares by company officers to cover tax obligations upon exercising stock options are a common practice.

Stakeholder Impact

• The sale of shares by an officer could have a minor impact on shareholder sentiment, but is unlikely to be significant given the context.

Key Dates